Supraflex for high-risk patients and lesions: from practice to evidence-based medicine proven through FIRE and COMPARE
<p class="moderator speaker-name">Anchorperson: <span classs="personname">Patrick Serruys</span></p><p class="moderator speaker-name">Spokesperson: <span classs="personname">Yoshinobu Onuma</span></p><p class="moderator speaker-name">Discussants: <span classs="personname">Ana Belen Cid Alvarez, Jacek Legutko, Raul Moreno, Helge Möllmann, Ashok Seth, Joanna Wykrzykowska</span></p><p class="moderator speaker-name">Guest speakers: <span classs="personname">Atul Abhyankar, Gianluca Campo, Anuruck Jeamanukoolkit, David Leistner, Tsung-Ying Tsai</span></p>
Watch this session if you want
<ul> <li>To understand the coverage of thin strut sirolimus DES in small vs. large vessel, in diabetes, and in STEMI with OCT analysis</li> <li>To understand the performance of the Supraflex stent for high-risk patients such as high bleeding risk or the elderly</li> <li>To preview the anticipated outcomes of two major randomised trials in patients with triple vessel disease, with or without diabetes</li> </ul>
<div class="intervention"><div class="interventionTitle">Welcome and session objectives</div><p class="speaker-intervention-name-img">Patrick Serruys</p></div><div class="intervention"><div class="interventionTitle">Two-year follow-up of live case performed in Toulouse: left main bifurcation guided by coronary CT angiography and OCT</div><p class="speaker-intervention-name-img">Tsung-Ying Tsai</p></div><div class="intervention"><div class="interventionTitle">The coverage of thin strut sirolimus DES in small vs. large vessel, in diabetes, and in STEMI with OCT analysis</div><p class="speaker-intervention-name-img">Atul Abhyankar</p></div><div class="intervention"><div class="interventionTitle">Evidence of Supraflex in high bleeding risk patients: the EARTH HBR study: a pooled analysis of nearly 1000 patients with one-month DAPT from the FIRE, COMPARE60/80, Cruz HBR studies</div><p class="speaker-intervention-name-img">Gianluca Campo</p></div><div class="intervention"><div class="interventionTitle">Evidence of Supraflex in octogenarian patients: the Cruz Senior registry</div><p class="speaker-intervention-name-img"></p></div><div class="intervention"><div class="interventionTitle">Pre-recorded case: complex PCI in an elderly patient</div><p class="speaker-intervention-name-img">Anuruck Jeamanukoolkit</p></div><div class="intervention"><div class="interventionTitle">What to expect about Supraflex in 2025: randomised comparison of device success: Synergy vs. Supraflex according to EAPCI criteria</div><p class="speaker-intervention-name-img">Patrick Serruys</p></div><div class="intervention"><div class="interventionTitle">What to expect about Supraflex at the 2025 (teaser): MVT outcome prediction</div><p class="speaker-intervention-name-img">Yoshinobu Onuma</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div><div class="intervention"><div class="interventionTitle">Session evaluation and key learnings</div><p class="speaker-intervention-name-img">Yoshinobu Onuma</p></div>
